Kilitch Drugs (India) Ltd. reported a net profit of ₹1,351.01 lakhs for the second quarter of fiscal year 2025, marking a notable performance amidst fluctuating market conditions. The company's earnings were bolstered by a total income of ₹4,542.24 lakhs, which included net sales from operations amounting to ₹3,781.35 lakhs and other income of ₹760.89 lakhs for the quarter ending September 30, 2025. This development was disclosed following a Board meeting held on November 13, 2025, where the unaudited financial results were approved.

In terms of expenses, Kilitch Drugs incurred total expenses of ₹3,534.85 lakhs, reflecting a comprehensive approach to managing costs. The company reported a profit before tax of ₹1,007.39 lakhs, highlighting its strong operational efficiency. On the balance sheet, Kilitch Drugs showed robust growth, with assets totaling ₹44,314.94 lakhs, attributed to increased investments in property and equipment as well as strong cash positions. The company successfully completed a rights issue of 13,98,463 equity shares at ₹357 each, raising significant capital for its Greenfield project.

The earnings per share (EPS) for the quarter stood at ₹5.27, slightly lower than the same quarter last year, which had an EPS of ₹5.50. However, the overall financial health of Kilitch Drugs remains solid, with a positive outlook driven by strategic investments and a focus on expanding its market presence. The results reflect the company's commitment to growth and operational excellence, positioning it favorably in the competitive pharmaceutical landscape.